Recordati Industria Chimica e Farmaceutica S.p.A. (0KBS.IL)

Compare

50.90

-0.57

(-1.12%)

At close: April 4 at 6:57:34 PM GMT+1

3 European Stocks Estimated To Be Undervalued In March 2025

As European markets navigate a complex landscape of mixed inflation data and economic contractions in major economies like Germany and France, the pan-European STOXX Europe 600 Index has shown resilience by posting its longest streak of weekly gains since August 2012. Against this backdrop, identifying stocks that may be undervalued becomes particularly pertinent for investors seeking opportunities amidst uncertainty.

Simply Wall St. last month

RCDTF

RICFY

SFRGF
RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4%PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS Consolidated net revenue of € 2,341.6 million for FY 2024, +12.4% or +9.2% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 865.8 million, +12.5%, revenue margin of 37.0% Adjusted net income(2) of € 568.9 million, +8.4% Net income of € 416.5 million, +7.0% Free cash flow(4) at € 535.1 million, +

GlobeNewswire last month

RCDTF

RICFY
3 Companies That May Be Trading Below Their Estimated Value

As global markets navigate the evolving economic landscape, U.S. stocks have been marching toward record highs, buoyed by optimism around potential trade deals and AI-related developments. Despite these gains, growth stocks have outperformed value shares, highlighting opportunities for investors to explore companies that may be trading below their estimated value. Identifying undervalued stocks often involves assessing a company's fundamentals and market position relative to current economic...

Simply Wall St. 2 months ago

RCDTF

RICFY
Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Recordati SpA (RICFY) reports a 12% revenue increase and confirms full-year targets despite challenges in Turkey and the US market.

GuruFocus.com 4 months ago

RICFY

SNY
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

Consolidated net revenue of € 1,743.1 million in the first nine months, +12.0% or +9.3% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 665.7 million, +11.8%, revenue margin of 38.2% Adjusted net income(2) of € 445.4 million, +9.5% Net income of € 338.4 million, +11.1% Free cash flow(4) at € 434.3 million, +€ 42.5 million vs prior yearNet debt(5) at € 1,317.3 million, just below 1.6x EBITDAFinancial targets for FY 2024 confirmed, excluding any potential contributio

GlobeNewswire 4 months ago

RCDTF

RICFY
Recordati SpA (RICFY) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Recordati SpA (RICFY) reports a 30.5% increase in net revenue and upwardly adjusts its full-year financial targets, showcasing robust performance and strategic progress.

GuruFocus.com 5 months ago

RICFY
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati

On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional commercial milestone payments of up to $250 million. Enjaymo, a humanized monoclonal antibody, is the only approved targeted product for cold agglutinin disease (CAD), a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). Also Read: FDA Approves Regeneron/Sano

Benzinga 5 months ago

SNY

RICFY
Sanofi’s rare disease drug finds yet another home

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

BioPharma Dive 5 months ago

SNY

RICFY
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo

The strategic move is set to enhance Recordati's rare diseases franchise.

Pharmaceutical Technology 5 months ago

RICFY

SNY
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults with CAD. In 2022, it was granted approval by the U.S. Food and Drug Administration (FDA), the European Commi

GlobeNewswire 5 months ago

RCDTF

RICFY
UPDATE 1-CVC explores options for Italy's Recordati, Bloomberg News reports

CVC Capital Partners is exploring options for its controlling stake in Italian pharmaceutical group Recordati SpA, Bloomberg News reported on Tuesday, citing people familiar with the matter. CVC and Recordati did not immediately respond to a Reuters request for comments. A CVC-led consortium of investment funds had agreed to buy 51.8% of Recordati in a deal worth about 3 billion euros in 2018.

Reuters 11 months ago

RICFY

Performance Overview

Return	0KBS.IL	FTSE MIB Index (FTSEMIB.MI)
YTD	+0.16%	+1.35%
1-Year	+4.46%	+0.56%
3-Year	+16.57%	+37.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Recordati Industria Chimica e Farmaceutica S.p.A. (0KBS.IL)

3 European Stocks Estimated To Be Undervalued In March 2025

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

3 Companies That May Be Trading Below Their Estimated Value

Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

Recordati SpA (RICFY) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati

Sanofi’s rare disease drug finds yet another home

Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

UPDATE 1-CVC explores options for Italy's Recordati, Bloomberg News reports

Performance Overview